Our study reported the response rate was 17.6% for ESCC patients with high EGFR-expressing tumors, which was markedly higher than the rate (0%) for patients with low to moderate EGFR-expressing tumors. The gene discussed is EGFR; the disease is esophageal squamous cell carcinoma.